CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1M, lower than 95% of all stocks globally
- PositionOperating margin is -5258.3%, lower than 95% of its Biotechnology peers (median -34.2%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
719.18MUSDvs all stocks (USD)
Revenue (TTM)
1.00MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.06xvs all stocks
52-Week Change
880.49%vs all stocks
Market Capitalization
719.18MUSDvs all stocks (USD)
Enterprise Value
489.87MUSDvs all stocks (USD)
Forward P/E
-14.60xvs Biotechnology peers
Price to Book (MRQ)
5.94xvs Biotechnology peers
Enterprise to Revenue
489.87xvs Biotechnology peers
Enterprise to EBITDA
-10.01xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-36.66%vs Biotechnology peers
Return on Equity (TTM)
-61.04%vs Biotechnology peers
Revenue (TTM)
1.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0120USDUpdated Jul 19, 2026Gross Profit (TTM)
-2.98MUSDvs all stocks (USD)
EBITDA (TTM)
-48.94MUSDvs all stocks (USD)
Net Income (TTM)
-49.87MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-41.27MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-22.42MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.00MUSDFY2025 · Dec 31, 2025Operating Income
-51.51MUSDvs all stocks (USD)
Pre-tax Income
-48.81MUSDFY2025 · Dec 31, 2025Net Income
-48.81MUSDFY2025 · Dec 31, 2025EBIT
-51.51MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-47.82MUSDFY2025 · Dec 31, 2025Research & Development
35.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
17.23MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.70MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-48.81MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-39.89MUSDFY2025 · Dec 31, 2025Free Cash Flow
-39.96MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
54.19MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-48.81MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.69MUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-599.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-318.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-843.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-71.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-43.42MUSDFY2025 · Dec 31, 2025Sale of Investments
35.60MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-7.89MUSDFY2025 · Dec 31, 2025Other Financing Charges
-65.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
44.41MUSDFY2025 · Dec 31, 2025Shares Outstanding
75.58MSharesUpdated Jul 19, 2026Float Shares
46.85MSharesUpdated Jul 19, 2026Shares Short
5.93MSharesUpdated Jul 19, 2026Short Ratio
3.21daysvs all stocks
Short % of Shares Outstanding
6.44%vs all stocks
% Held by Insiders
4.53%vs all stocks
% Held by Institutions
59.56%vs all stocks
Total Cash (MRQ)
90.42MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.18USDUpdated Jul 19, 2026Total Debt (MRQ)
2.89MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0301xvs Biotechnology peers
Current Ratio (MRQ)
22.07xvs Biotechnology peers
Book Value per Share (MRQ)
1.27USDUpdated Jul 19, 2026Total Assets
91.03MUSDvs all stocks (USD)
Total Current Assets
82.47MUSDFY2025 · Dec 31, 2025Total Liabilities
8.64MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.55MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.58MUSDFY2025 · Dec 31, 2025Total Current Liabilities
7.05MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
54.19MUSDFY2025 · Dec 31, 2025Other Short-term Investments
23.87MUSDFY2025 · Dec 31, 2025Accounts Payable
2.10MUSDFY2025 · Dec 31, 2025Short-term Debt
837.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
236.00KUSDFY2025 · Dec 31, 2025Long-term Debt
1.58MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-430.53MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
82.39MUSDvs all stocks (USD)
52-Week Low
0.7120USDUpdated Jul 19, 202652-Week High
8.33USDUpdated Jul 19, 202652-Week Change
880.49%vs all stocks
Beta
1.06xvs all stocks
50-Day MA
5.95USDUpdated Jul 19, 2026200-Day MA
4.57USDUpdated Jul 19, 2026Avg 10-Day Volume
1.57MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.85MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.5600USDUpdated Jul 19, 2026Other Income / Expense
-4.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -5258.3%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -52.58Industry median: -0.34Industry P5: -43.55Peers compared: 261
Financial Health
Consistent revenue growth patternNotable
Growth Consistency Score: 0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,000,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Beilu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aura Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Climb Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shenzhen Lifotronic Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Getein Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ceribell, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senores Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
SS Innovations International, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
MongoDB Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Erasca, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Relay Therapeutics Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity